Neuroendocrine Tumors
Conditions
Brief summary
Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the 111In - DTPA-octreotide.
Interventions
OTHER99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide
The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
Sponsors
Financiadora de Estudos e Projetos
Instituto do Cérebro do Rio Grande do Sul - InsCer
Latin American Cooperative Oncology Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histological diagnosis of neuroendocrine tumors * Patients with indication for the staging exam with 11In * Patients diagnosed in any tumor stage * Patients with \> 18 years * Male and female patients * Patients not receiving somatostatin analogues for at least 1 month before image capturing
Exclusion criteria
* Pregnant women * Patients with previous tumor resection of the primary tumor without metastatic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of the images captured with 99m Tc - HYNIC -TOC EDDA ( octreotide labeled with 99mTc ) and 111In - DTPA-octreotide for the diagnosis of neurocrine tumors | Up to 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Visualization of the ocurrence of the neuroendocrine tumor lesions with both radiopharmaceutical agents | Up to 30 days |
| Number of neuroendocrine tumor lesions visualized with both radiopharmaceutical agents | Up to 30 days |
Countries
Brazil
Outcome results
None listed